[Form 4] NovoCure Ltd Insider Trading Activity

Rhea-AI Filing Summary

NovoCure Ltd. (NVCR) reported insider activity by Chief Operating Officer Mukund Paravasthu related to RSU vesting tax withholding. On 11/01/2025, the issuer withheld 168 ordinary shares at $12.81 per share. On 11/04/2025, the issuer withheld an additional 2,949 ordinary shares at $12.23 per share. These are coded “F” transactions, reflecting shares withheld to satisfy tax obligations and described as non-discretionary. Following these transactions, Paravasthu directly beneficially owned 80,439 ordinary shares.

Insights

Equity compensation analyst

Non-discretionary RSU tax withholdings; neutral signal.

The filing lists two Code F transactions tied to RSU vesting, where the issuer withholds shares to cover taxes. The amounts are 168 shares at $12.81 on 11/01/2025 and 2,949 shares at $12.23 on 11/04/2025, as described in the explanation of responses.

Code F events are administrative rather than open‑market trades. The filing notes the action is not discretionary and references approval under Rules 16b‑3(e) and 16b‑3(d)(1). After these events, direct beneficial ownership stands at 80,439 shares.

Because these are routine tax withholdings tied to equity vesting, they typically do not alter the investment thesis. Any impact depends on ongoing equity award schedules and future vesting activity disclosed in subsequent filings.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Paravasthu Mukund

(Last) (First) (Middle)

C/O NOVOCURE INC.

1550 LIBERTY RIDGE DRIVE, SUITE 115

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	11/01/2025		F		168(1)	D	$12.81	83,388	D
Ordinary Shares	11/04/2025		F		2,949(1)	D	$12.23	80,439	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1).

Remarks:

	Steven Robbins, as attorney in fact for Paravasthu, Mukund	11/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did NovoCure (NVCR) report?

Two Code F entries: issuer withheld shares to cover RSU tax obligations on 11/01/2025 and 11/04/2025.

How many NVCR shares were withheld for taxes and at what prices?

168 shares at $12.81 on 11/01/2025 and 2,949 shares at $12.23 on 11/04/2025.

Who is the reporting person in this Form 4 for NVCR?

Mukund Paravasthu, Chief Operating Officer of NovoCure Ltd.

How many NovoCure shares did the insider own after the transactions?

Direct beneficial ownership was 80,439 ordinary shares following the reported transactions.

Were these open‑market sales by the NVCR insider?

No. The filing explains they were non-discretionary share withholdings to satisfy RSU tax obligations (Code F).

Was a Rule 10b5‑1 trading plan indicated?

The form includes a 10b5‑1 checkbox section, but the excerpt does not indicate it was selected.